Veterinary Pharmaceuticals Market Overview
The global veterinary pharmaceuticals market is projected to grow from USD 28.98 billion in 2026 to USD 39.37 billion by 2031, registering a CAGR of 6.3% during the forecast period. Rising pet ownership, expanding livestock production, increasing awareness of animal health, and continuous innovation in biologics and preventive medicines are accelerating market growth worldwide.
Veterinary pharmaceuticals play a vital role in preventing, diagnosing, and treating diseases in companion animals and livestock. The growing importance of animal welfare, food security, and zoonotic disease prevention is encouraging governments, veterinarians, livestock producers, and pet owners to invest more heavily in advanced veterinary healthcare solutions.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243381376
Key Market Highlights
- Market Size (2026): USD 28.98 Billion
- Projected Market Size (2031): USD 39.37 Billion
- CAGR (2026–2031): 6.3%
- Growth Drivers:
- Rising global pet ownership
- Increasing livestock production
- Growing expenditure on animal healthcare
- Strong demand for vaccines and preventive medicines
- Technological advancements in biologics and monoclonal antibodies
- Expansion of veterinary infrastructure in emerging economies
Rising Pet Ownership Fuels Veterinary Pharmaceutical Demand
The growing emotional bond between people and their pets has significantly increased spending on companion animal healthcare. Pet owners are seeking advanced treatments that improve quality of life while preventing chronic diseases.
Demand is particularly strong for:
- Long-acting pain management therapies
- Vaccines
- Anti-infectives
- Parasiticides
- Dermatology treatments
- Oncology therapies
- Monoclonal antibody treatments
Companion animal healthcare has become one of the fastest-growing segments within the veterinary pharmaceuticals industry, supported by higher veterinary visits, pet insurance adoption, and improved access to specialized veterinary care.
Livestock Industry Drives Pharmaceutical Consumption
The expansion of commercial livestock farming continues to create strong demand for veterinary pharmaceuticals.
Increasing production of:
- Poultry
- Cattle
- Swine
- Sheep
- Aquaculture
requires effective disease prevention, vaccination programs, parasite management, and therapeutic interventions.
Governments and food producers are emphasizing:
- Animal productivity
- Disease control
- Food safety
- Reduced economic losses
- Improved animal welfare
These factors continue to boost pharmaceutical adoption across livestock production systems.
Preventive Animal Healthcare Becoming the Industry Standard
Preventive healthcare has become one of the biggest trends in veterinary medicine.
Veterinarians increasingly recommend:
- Routine vaccinations
- Preventive parasite control
- Long-acting injectables
- Nutritional supplements
- Regular health monitoring
These preventive approaches reduce disease outbreaks while lowering long-term treatment costs and improving animal longevity.
The shift toward prevention is expected to remain a major growth driver throughout the forecast period.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=243381376
Innovation in Biologics Transforming Veterinary Medicine
Biologics are reshaping veterinary therapeutics by offering targeted, long-lasting, and highly effective treatment options.
Major innovations include:
- Monoclonal antibodies
- Therapeutic vaccines
- Recombinant proteins
- Precision biologics
- Long-duration injectable therapies
These technologies are improving treatment outcomes for chronic diseases, osteoarthritis, dermatological disorders, and immune-mediated conditions in companion animals.
As research investments continue, biologics are expected to capture an increasing share of the veterinary pharmaceuticals market.
Emerging Markets Present Significant Growth Opportunities
Asia-Pacific and Latin America are becoming major growth engines for the veterinary pharmaceuticals industry.
Several factors contribute to this expansion:
- Rising disposable incomes
- Growing livestock populations
- Increasing pet adoption
- Expanding veterinary clinics
- Government support for animal disease control
- Improved pharmaceutical distribution networks
Countries such as India, China, Brazil, and Southeast Asian nations are expected to witness rapid adoption of advanced veterinary medicines over the coming years.
Recent Industry Developments
The veterinary pharmaceuticals market continues to witness strategic product launches, acquisitions, and regulatory approvals.
Zoetis Introduces Long-Acting Osteoarthritis Therapy
In October 2025, Zoetis Inc. received approval in Canada for Leniva, a long-acting monoclonal antibody designed to treat canine osteoarthritis pain.
Administered once every three months, Leniva strengthens Zoetis’ companion animal pain management portfolio while highlighting the growing importance of biologic therapies.
Merck Animal Health Expands Preventive Care Portfolio
In July 2025, Merck & Co., Inc. received US FDA approval for BRAVECTO QUANTUM, a once-yearly injectable treatment protecting dogs against fleas and ticks.
The product significantly improves treatment compliance while reinforcing Merck’s leadership in companion animal preventive healthcare.
Merck Strengthens Aquaculture Business
In July 2024, Merck completed the USD 1.29 billion acquisition of Elanco’s aquaculture business.
The acquisition expanded Merck’s portfolio of:
- Fish vaccines
- Aquatic medicines
- Nutritional solutions
while strengthening its position in global aquaculture health.
Boehringer Ingelheim Expands Biologics Capabilities
In September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG, enhancing its pipeline for chronic disease vaccines and next-generation biologics designed for companion animals.
Leading Companies Operating in the Veterinary Pharmaceuticals Market
The market features several global companies investing heavily in innovation, manufacturing expansion, biologics development, and strategic acquisitions.
Key market participants include:
- Zoetis Inc. (US)
- Merck Animal Health (US)
- Boehringer Ingelheim Animal Health (Germany)
- Elanco (US)
- Virbac (France)
- Ceva (France)
- Vetoquinol (France)
- Dechra Pharmaceuticals (UK)
- Norbrook (UK)
- Bimeda (Ireland)
- Hester Biosciences Limited (India)
- Indian Immunologicals Ltd. (India)
- Animalcare Group (UK)
- Kyoritsu Seiyaku (Japan)
- Calier (Spain)
Company Profiles
Zoetis Inc. (US)
Zoetis is the world’s largest pure-play animal health company, offering a comprehensive portfolio of medicines, vaccines, diagnostics, and precision animal health technologies. Operating in more than 100 countries, the company serves both companion animals and livestock through innovative therapeutics, parasiticides, vaccines, pain management solutions, and diagnostic products. Its continued investment in biologics and digital animal health strengthens its leadership position globally.
Merck Animal Health (US)
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, delivers vaccines, pharmaceuticals, biologics, and digital monitoring technologies for livestock and companion animals. With operations spanning over 140 countries, 25 manufacturing facilities, and 16 research centers, the company continues expanding its global footprint through strategic acquisitions and innovative preventive healthcare products.
Boehringer Ingelheim Animal Health (Germany)
Boehringer Ingelheim maintains one of the industry’s broadest veterinary portfolios covering vaccines, parasiticides, therapeutics, and biologics for companion and production animals. Supported by extensive research capabilities and a global distribution network, the company continues investing in innovative chronic disease treatments and next-generation biologics that improve long-term animal health outcomes.
Competitive Landscape
Competition within the veterinary pharmaceuticals market is characterized by continuous innovation, regulatory approvals, acquisitions, and expansion into high-growth emerging markets.
Leading companies are focusing on:
- Developing monoclonal antibodies
- Launching long-acting injectable therapies
- Expanding biologics portfolios
- Investing in precision animal health
- Strengthening vaccine pipelines
- Enhancing global manufacturing capabilities
- Expanding digital veterinary solutions
Zoetis maintains market leadership through its dedicated animal health strategy and broad product portfolio. Merck Animal Health leverages strong research capabilities and preventive medicine expertise. Boehringer Ingelheim continues advancing biologics innovation, while Elanco strengthens its market position through acquisitions and diversified product offerings. Virbac remains highly competitive through its specialization in companion animal therapeutics and expanding presence across emerging markets.
Future Outlook
The future of the veterinary pharmaceuticals market remains highly promising as companion animal care continues to evolve alongside modern livestock production systems. Growing awareness of preventive healthcare, expanding adoption of biologics, technological advances in veterinary therapeutics, and increasing investment in animal welfare will continue driving sustainable market growth.
As pharmaceutical companies introduce innovative vaccines, monoclonal antibodies, targeted therapies, and long-acting formulations, veterinarians and animal owners will gain access to safer, more effective, and convenient treatment options. Combined with expanding veterinary infrastructure across developing economies, these trends are expected to propel the veterinary pharmaceuticals market to USD 39.37 billion by 2031, making animal healthcare one of the fastest-evolving segments of the global life sciences industry.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=243381376